Defining the Expectations of Your Center’s Leaders

1. Defining the Expectationsof Your Center’s Leaders Cancer Center Administrators’ Forum April 2011

2. Cancer Center Leadership Roles • Cancer Center Director: this role is usually well defined both by the NCI CCSG guidelines and by the institution • Vision/strategic planning - Budget • Recruitment - Fundraising • Equivalent to departmental chair - Space • Deputy Director, Associate Directors, Program Leaders and Shared Resource Directors • Often times the authority, expectations and responsibilities of these positions are ill defined

3. Today’s Presentations • Associate Director Role • Anita Harrison, Hollings Cancer Center, MUSC • Melanie Thomas, Associate Director of Clinical Investigations • Program Leader Role • Kimberly Kerstann, Winship Cancer Institute, Emory • Paula Vertino, Cancer Genetics & EpigeneticsProgram Leader • Shared Resource Director Role • Stephen Long, Greenebaum Cancer Center, U of Maryland • Nicholas Ambulos, Director of Shared Services

4. Associate Director • Common Cancer Center Associate Director Positions • Basic Science - Prevention & Control • Clinical Investigations - Cancer Disparities • Translational Research - Administration • Shared Resources - Clinical Affairs • Education • Generally, these positions are considered the Center’s “Senior Leadership” and report to the Director or Deputy Director • Typically, they receive CCSG support for 10-20% effort; total Center support can be up to 50% • Meet 1-2 times a month as a group with Director/Deputy

5. Associate Directors • Formulate priorities, strategies and provide input into the allocation of resources • Closely monitor the strength of several of the CCSG Essential Characteristics (cancer focus, research facilities, inter/transdisciplinary interactions, organizational capabilities) across the Center • Evaluate Center’s progress in meeting strategic planning goals • Expected to be inter-connected with other departmental/college/campus-wide efforts to build synergy with the Cancer Center

6. Defining the Associate Director’s Role • Create a job description for each • Role should be distinct from other roles but clarify any areas of overlap and make sure that these are well articulated • Associate Director (Breadth) vs Program Leader (Depth) • Define what financial resources they have to accomplish their job and/or what part of the Center’s budget are they accountable for • Effectiveness should be annually reviewed (peer review by other Associate Directors and Program Leaders; EAB)

7. Associate Director of Clinical Investigations Melanie B. Thomas, MD Associate Professor of MedicineGrace E. DeWolff Chair in GI Oncology • Recruited in 2008 from University of Texas M.D. Anderson Cancer Center • Nationally-recognized for her multidisciplinary clinical research program in hepatobiliary cancer • 2009 NCI Clinical Leadership Team Award • Cancer Center supports 30% effort for this role

8. Authorities and Responsibilities

9. Authorities and Responsibilities • Identify clinical research expertise needed and work with Director and institutional leaders (dept, divisions) to facilitate faculty recruitment • Integrate investigators into multidisciplinary groups in which they are actively engaged with basic and population based researchers in developing translational research

10. Clinical and Laboratory Interface Established Disease-based Research Groups with Key Clinical Faculty Hem/Mal Neuro Thoracic GU H&N Breast GI Kraft Drabkin KeaneGolshayan DayGillespieShirai Sharma Thomas Esnaola Chin Camp ReedDenlinger SilvestriSimon StuartKravekaHudspethCosta Baker JenretteKramerChristiansen GiglioPatel TRANSLATIONAL RESEARCH CancerPrevention& Control Cancer Genes & Molecular Regulation Lipid Signaling in Cancer Developmental Cancer Therapeutics Cancer Immunology HCC Research Programs

11. Authorities and Responsibilities • Promotion of investigator initiated trials, especially with Center’s pre-clinical investigators • Develop consortium relationships with NCI Phase I and Phase II awardees as well as industry partners to develop and conduct novel trials • Promotion and facilitation of the development of leadership within cooperative groups • Increase clinical trial accrual; work with Associate Director of Cancer Disparities to promote minority participation

12. Strategies Employed • ExPERT – junior clinical investigators meet monthly with Dr. Thomas and invited shared resource directors and program leaders to discuss correlative science concepts • Pfizer 3D Program (Sept 2010) • Disease & Program Retreats 10 in 2010 • Abney Clinical Scholars – HCC salary support for new junior faculty for protected time (Graybill, Young) • Ongoing faculty recruitment – 2010 • HCC further investing in CTO to support accrual/protocol development (VA, East Cooper, Phase I)

13. Shifting the Portfolio Toward IITs 2008 (N=122) HCC Active Therapeutic Studies by Sponsor 2011 (N=126) 2 Active Phase I Trials in 2008 10 Active Phase I Trials in 2011

14. 15 by 2015The Next Breakthrough Could Be Yours • Less than 1% of adults in SC diagnosed with cancer enroll on a therapeutic clinical trial • 254 patients (12.4% of new patients) enrolled onto a therapy trial at the HCC in 2010 • HCC led statewide public policy changes in 2010 to ensure every person with insurance has access to cancer clinical trials • The HCC goal is to increase enrollment to therapy trials to 15% by 2015

15. 15 by 2015The Next Breakthrough Could Be Yours • Goals: - Raise everyone's awareness of clinical trials - Integrate clinical trials into all standard pt care practices - Foster culture that values and promotes faculty/staff involvement in clinical trials • Strategies: - Continual rounding with faculty/staff about clinical trials - Identify and knock down ALL barriers to enrolling - Visuals: banners (12), posters (80), buttons, info cards - Commitment by MUSC leadership to hold faculty/staff accountable for growth in clinical trials

16. 15 by 2015The Next Breakthrough Could Be Yours HCC Therapeutic Accrual to Cancer Clinical Trials(assumes a 3% growth in overall pt volume/year)